

References

S-214

1. InterQual® Level of Care Criteria 2019, Acute Care Adult, McKesson Health Solutions, LLC
2. American Cancer Society. What's New in Acute Myeloid Leukemia Research and Treatment? Revised February 22, 2016.
3. Master S, Mansour R, Devarakonda SS, et al. Predictors of survival in acute myeloid leukemia by treatment modality. *Anticancer Res.* 2016;36(4):1719-1727.
4. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. *Haematol.* 2017;102(5):865–873.
5. Heidrich K, Thiede C, Schafer-Eckart K, et al. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. *Ann Oncol.* 2017;28(11):2793-2798.
6. Frazer J, Couban S, Doucette S, et al. Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. *Curr Oncol.* 2017;24(2):e123-e130.
7. Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. *Biol Blood Marrow Transplant.* 2016;22(4):651–657.
8. Shimoni A, Labopin M, Savani B, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. *J Hematol Oncol.* 2016;9(1):118.
9. Miyamoto T, Nagafuji K, Fujisaki T, et al. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. *Int J Hematol.* 2018;107(4):468-477.
10. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute myeloid leukemia. Version 3.2021.
11. Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: A primer. *Cancer.* 2020;126(21):4668-4677.
12. Koenig K, Mims A, Levis MJ, Horowitz MM. The changing landscape of treatment in acute myeloid leukemia. *Am Soc Clin Oncol Educ Book.* 2020;40:1-12.
13. Dholaria B, Savani BN, Hamilton BK, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: An evidence-based review from the American Society of Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* 2020;27:6-20.
14. Kawashima N, Ishikawa Y, Atsuta Y, et al. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. *Cancer Science.* 2020;111(7):2472-2481.
15. Hu G-H, Cheng Y-F, Lu A-D, et al. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. *BMC Cancer.* 2020;20(1):553.

16. Hunter BD, Chen Y-B. Current Approaches to Transplantation for FLT3-ITD AML. *Current Hematol Malign Rep.* 2020;15(1):1-8.